Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBIT: 2012-2025

Historic EBIT for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $3.0 million.

  • Ptc Therapeutics' EBIT rose 105.53% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.9 million, marking a year-over-year increase of 677.47%. This contributed to the annual value of -$302.6 million for FY2024, which is 31.16% up from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' EBIT is $3.0 million, which was up 108.63% from -$35.0 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year EBIT high stood at $970.2 million for Q1 2025, and its period low was -$209.5 million during Q2 2023.
  • For the 3-year period, Ptc Therapeutics' EBIT averaged around $17.8 million, with its median value being -$45.5 million (2024).
  • As far as peak fluctuations go, Ptc Therapeutics' EBIT plummeted by 2,890.19% in 2024, and later soared by 2,234.57% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' EBIT stood at -$84.7 million in 2021, then tumbled by 136.45% to -$200.3 million in 2022, then skyrocketed by 102.91% to $5.8 million in 2023, then tumbled by 2,890.19% to -$162.4 million in 2024, then spiked by 105.53% to $3.0 million in 2025.
  • Its EBIT stands at $3.0 million for Q3 2025, versus -$35.0 million for Q2 2025 and $970.2 million for Q1 2025.